Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Should Have Opdivo First-Line Lung Cancer Data In Weeks

Executive Summary

With Opdivo sales up to $840m in the second quarter, Bristol execs once again make the case for trial strategy in the all-important first-line lung cancer indication and say they look forward to the CheckMate 026 data “in weeks not months.”

Advertisement

Related Content

Fourth EU Opdivo Approval Pending, But BMS Won't Gain Much
Does CheckMate 026 Take Bristol Out Of The End Game?
Merck Defends Its Offensive Strategy For Keytruda
Bristol's Oncology Strategy: Cover All The Bases To Keep The Lead
Bristol Pushes Pedal To Metal In Immuno-Oncology Combo Testing
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel